Novo Nordisk Beheer

Beheer criteriumcontroles 3/4

De CEO Novo Nordisk is Lars Jorgensen, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde MX$ 189.47M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 6.7 jaar.

Belangrijke informatie

Lars Jorgensen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.8yrs
Eigendom CEO	0.002%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	6.7yrs

Recente managementupdates

Geen updates

Recent updates

Analyse CEO-vergoeding

Hoe is Lars Jorgensen's beloning veranderd ten opzichte van Novo Nordisk's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	DKK 95b
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Lars redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de MX markt.

Compensatie versus inkomsten: De vergoeding van Lars is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Tenure

DKK 60,100,000

Compensatie

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% MX$ 189.5m
Karsten Knudsen	Executive VP	6.8yrs	DKK 21.50m	0.000010% MX$ 906.6k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% MX$ 5.4m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	geen gegevens
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	geen gegevens
Marcus Schindler	EVP of Research & Early Development	3.7yrs	DKK 20.90m	geen gegevens
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	geen gegevens	0.0011% MX$ 102.4m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	geen gegevens	geen gegevens
Ludovic Helfgott	Executive VP	no data	geen gegevens	geen gegevens
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.7yrs	geen gegevens	geen gegevens
David Moore	Executive VP of Corporate Development & Member of Management Board	1.7yrs	geen gegevens	geen gegevens
Jacob Martin Rode	Head of Investor Relations	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVO N wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sylvie Gregoire	Independent Director	9.7yrs	DKK 1.80m	geen gegevens
Helge Lund	Independent Chairman of the Board	7.7yrs	DKK 3.10m	geen gegevens
Henrik Poulsen	Vice Chairman of the Board	3.7yrs	DKK 2.00m	geen gegevens
Laurence Debroux	Independent Director	5.7yrs	DKK 2.00m	geen gegevens
Martin MacKay	Independent Director	6.7yrs	DKK 1.70m	geen gegevens
Andreas Fibig	Independent Director	6.7yrs	DKK 1.40m	geen gegevens
Kasim Kutay	Non-Independent Director	7.7yrs	DKK 1.20m	geen gegevens
Christina Law	Independent Director	2.7yrs	DKK 1.30m	geen gegevens
Liselotte Hyveled	Employee Representative Director	2.7yrs	DKK 800.00k	0% MX$ 0
Mette Jensen	Employee Non-Independent Representative Director	6.7yrs	DKK 1.20m	geen gegevens
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	geen gegevens
Elisabeth Christensen	Employee Representative Director	2.7yrs	DKK 800.00k	geen gegevens

6.7yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVO N wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).

Novo Nordisk Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Recent updates

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd